NEW YORK, NY--(Marketwired - Nov 12, 2013) - IntelliCell Biosciences, Inc. (
It is important to note that by "successful," the company is declaring that these cells do not cure Multiple Sclerosis, but of the 19 patients with MS that ReGen Medical has treated using IntelliCell's technology, each have gained anywhere from good to significant quality of life improvements.
In almost every case that ReGen treated, as well as in this case, previous medical history stated the patients' Multiple Sclerosis had progressively worsened. In the case of this patient she had undergone seven years of progression since her original diagnosis. This patient was remitted to the care of Dr. Steven Victor of ReGen Medical PC, where the patient received six treatments of ReGen Medical's proprietary SVFC, which includes stem cells, spaced approximately 3-5 months apart. The results of the treatment reflected significant improvements to the patient's quality of living. Prior to any SVFC treatments, the patient experienced a gradual decline, beginning in 2001, of her vision, bladder control, and mobility, particularly of the extremities on her right side. This culminated in her diagnosis of stage IV multiple sclerosis in 2006. Following the first treatment, the patient regained use of her previously immobile right leg, and coupled with more treatments and physical therapy, the patient can now walk. After her second treatment, the patient noticed more strength and agility in her previously clenched right hand. Additionally, with further treatment the patient noted drastically improved vision in her previously debilitated eye and she regained bladder control. With each patient ReGen Medical has treated, the number of treatments has varied between one and six, each patient experiencing different improvements at various intervals.
Dr. Steven Victor, CEO of IntelliCell Biosciences, commented, "The patient mentioned in this release, was the first clinical case we treated for MS with IntelliCell's SVFC technology. If not for our beneficial treatments, this patient would be restricted to a wheelchair and lose total sight in one of her eyes. Previously, this patient had been unsuccessfully treated at some of the most respected Medical Centers in the country and received little or no improvement to her symptoms. By utilizing IntelliCell's paradigm shifting medical solutions, we have dramatically improved the quality of this patient's life. IntelliCell is confident that the future of medicine will entail utilizing cellular therapy for previously unmet clinical needs, and we expect to establish ourselves as a market leader in this emerging industry."
Multiple Sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is an inflammatory disease in which the insulating covers, called myelinsheaths, of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may go away completely; however, permanent neurological problems often occur, especially as the disease advances.
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.